Literature DB >> 2114936

Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease.

R Foa1, M Massaia, S Cardona, A G Tos, A Bianchi, C Attisano, A Guarini, P F di Celle, M T Fierro.   

Abstract

Tumor necrosis factor-alpha (TNF) is a cytokine that displays a pleomorphic array of effects on different cell populations. Evidence is presented that TNF may be constitutively produced by B-cell chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells and that it may play a relevant role in these diseases. These conclusions are based on the presence of circulating levels of TNF in the serum of 20 of the 24 patients tested (83.3%), while undetectable values were found in normal sera. The suggestion that the increased serum levels were due to the leukemic cell population is strengthened by the evidence that purified B-CLL and HCL cells may constitutively release variable degrees of TNF. These levels markedly increase after incubation with interferon gamma or phytohemagglutinin (PHA) plus phorbol myristate acetate (PMA). The cellular release of TNF by primary B-CLL cells was significantly (P less than .001) higher in B-CLL stage O-I patients compared with stage II-III patients. The demonstration that, in B-cell chronic lymphoproliferative disorders, the pathologic cells may release TNF was further confirmed by the presence of the mRNA for this cytokine in primary and/or in pre-activated cells. Recombinant TNF was capable of inducing a proliferative signal only in a minority of cases (4/24); in most cases it was ineffective, and, in a few, it reduced the degree of proliferation. Furthermore, in costimulatory experiments with interleukin-2 and PHA plus PMA, TNF was ineffective. On the other hand, when primary B-CLL cells were incubated in the presence of an anti-TNF antibody, in 8 of 12 independent experiments a 2- to 15-fold increase in thymidine uptake was documented. Taken together, these results suggest that TNF may play a regulatory role in the progression of the neoplastic clone in B-cell chronic lymphoproliferative disorders and may be implicated in some of the side effects associated with these diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114936

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

3.  IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells.

Authors:  Lin Gui; Qingyu Zeng; Zhigang Xu; Hai Zhang; Shanshan Qin; Chunxiao Liu; Chong Xu; Zhou Qian; Shuangquan Zhang; Shile Huang; Long Chen
Journal:  Cytokine       Date:  2016-05-25       Impact factor: 3.861

Review 4.  In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.

Authors:  Chun-Ming Huang; Teruaki Nakatsuji; Yu-Tseung Liu; Yang Shi
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-01       Impact factor: 4.169

5.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  CD23 antigen regulation and signaling in chronic lymphocytic leukemia.

Authors:  S Fournier; G Delespesse; M Rubio; G Biron; M Sarfati
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

7.  Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection.

Authors:  A Kalinkovich; H Engelmann; N Harpaz; R Burstein; V Barak; I Kalickman; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

8.  Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF alpha/IFN alpha therapy.

Authors:  M Nagel-Hiemke; C Hiemke; G Kummer; T Moritz; H Müller; S Seeber; N Niederle
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

Review 9.  Expression, regulation and function of human Fc epsilon RII (CD23) antigen.

Authors:  M Sarfati; S Fournier; C Y Wu; G Delespesse
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 10.  Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review.

Authors:  M Schuler; C Huber; C Peschel
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.